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Abstract
Background
In South Africa, roughly half of the drug-resistant TB cases diagnosed are reported to have
been started on treatment. We determined the proportion of persons diagnosed with rifampi-
cin resistant (RR-) TB who initiated treatment in Johannesburg after the introduction of
decentralized RR-TB care in 2011.
Methods
We retrospectively matched adult patients diagnosed with laboratory-confirmed RR-TB in
Johannesburg from 07/2011-06/2012 with records of patients initiating RR-TB treatment at
one of the city’s four public sector treatment sites (one centralized, three decentralized).
Patients were followed from date of diagnosis until the earliest of RR-TB treatment initiation,
death, or 6 months’ follow-up. We report diagnostic methods and outcomes, proportions ini-
tiating treatment, and median time from diagnosis to treatment initiation.
Results
594 patients were enrolled (median age 34 (IQR 29–42), 287 (48.3%) female). Diagnosis
was by GenoType MTBDRplus (Hain-Life-Science) line probe assay (LPA) (281, 47.3%),
Xpert MTB/RIF (Cepheid) (258, 43.4%), or phenotypic drug susceptibility testing (DST) (30,
5.1%) with 25 (4.2%) missing a diagnosis method. 320 patients (53.8%) had multi-drug
resistant TB, 158 (26.6%) rifampicin resistant TB by Xpert MTB/RIF, 102 (17.2%) rifampicin
mono-resistance, and 14 (2.4%) extensively drug-resistant TB. 256/594 (43.0%) patients
initiated treatment, representing 70.7% of those who were referred for treatment (362/594).
338/594 patients (57.0%) did not initiate treatment, including 104 (17.5%) who died before
PLOS ONE | https://doi.org/10.1371/journal.pone.0181238 July 26, 2017 1 / 17
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Evans D, Schnippel K, Govathson C,
Sineke T, Black A, Long L, et al. (2017) Treatment
initiation among persons diagnosed with drug
resistant tuberculosis in Johannesburg, South
Africa. PLoS ONE 12(7): e0181238. https://doi.org/
10.1371/journal.pone.0181238
Editor: Pere-Joan Cardona, Fundacio´ Institut
d’Investigacio´ en Ciències de la Salut Germans
Trias i Pujol, Universitat Autònoma de Barcelona,
SPAIN
Received: June 27, 2016
Accepted: June 28, 2017
Published: July 26, 2017
Copyright: © 2017 Evans et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The data are owned
by the study sites and National Department of
Health (South Africa) and governed by the Human
Research Ethics Committee (University of the
Witwatersrand, Johannesburg, South Africa). The
full data are available from the Health Economics
and Epidemiology Research Office for researchers
who meet the criteria for access to confidential
data and have approval from the owners of the
data. Contact Naseem Ebrahim or Emma Llewellyn
treatment was started. The median time from sputum collection to treatment initiation was
33 days (IQR 12–52).
Conclusion
Despite decentralized RR-TB treatment, fewer than half the patients diagnosed in Johan-
nesburg initiated appropriate treatment. Offering treatment at decentralized sites alone is
not sufficient; improvements in linking patients diagnosed with RR-TB to effective treatment
is essential.
Introduction
In 2015, a global total of 132 120 cases of multi-drug resistant tuberculosis (MDR-TB) and
rifampicin resistant TB (RR-TB) were notified to the World Health Organization (WHO).
This represented 23% of the estimated 580 000 cases of MDR/RR-TB cases worldwide demon-
strating a major diagnostic gap [1].
South Africa, with less than 1% of the world’s population, accounted for 15% of the notified
cases of MDR/RR-TB globally, with 19 613 cases of laboratory confirmed MDR/RR-TB cases
in 2015 [1]. Although the proportion of eligible patients who initiated MDR-TB treatment in
South Africa increased from 41% in 2013 to 64% in 2015, a major diagnosis-to-treatment gap
remains [1,2]. Despite this increase, the proportion initiating MDR-TB treatment in South
Africa is below the global figure of 90% [3]. There is no possibility of achieving the Global Plan
to End TB by 2020 if a third of patients diagnosed with MDR/RR-TB never start treatment [1].
Prior to 2011, all patients with RR-TB in South Africa (a category that includes rifampicin
resistant TB with unknown additional drug resistance, MDR-TB, and extensively drug resis-
tant TB (XDR) TB were treated at specialized, inpatient facilities for the duration of the inten-
sive phase of drug resistant (DR-) TB treatment, typically six months [4]. Studies reported
that time from sputum collection to inpatient admission ranged from 10–16 weeks, and up to
40% of MDR-TB patients died within 30 days of sputum collection in certain provinces [5–7].
In 2011, South Africa improved its ability to test for DR-TB by introducing Xpert MTB/RIF
(Cepheid), a molecular test capable of identifying both TB and rifampicin resistance in under
two hours [8,9]. At the same time, in order to increase treatment capacity, minimize treatment
delays, and improve outcomes, the South African National TB program announced a frame-
work for “decentralized and deinstitutionalized management” of MDR-TB, authorizing outpa-
tient initiation of DR-TB treatment [10]. This policy allows patients to start treatment at sites
closer to their homes and remain resident at home for the duration of treatment, rather than
being isolated at one of the country’s few specialized, provincial-level inpatient TB hospitals.
Following implementation of the new policy, the number of sites initiating DR-TB treatment
quadrupled nationally, with at least one treatment site in each district [11].
To help inform further improvements in DR-TB programs and guidelines, we evaluated the
extent to which better diagnosis with Xpert MTB/RIF and decentralized service delivery has
improved DR-TB treatment initiation in South Africa. We conducted a retrospective medical
register review to match patients diagnosed with laboratory-confirmed RR-TB, as reported to
the City of Johannesburg in Gauteng Province, to DR-TB treatment initiation records at the
city’s four public sector treatment sites during the study period. We report diagnostic methods
and outcomes, proportions initiating treatment, and median time from diagnosis to treatment
initiation.
Drug resistant tuberculosis in South Africa—Linkage to care
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Methods
Setting, sites, and population
We conducted a retrospective medical register review of adult (18 years) patients with labo-
ratory-confirmed RR-TB between July 2011 and June 2012 in the City of Johannesburg (COJ),
the largest metropolitan area in the country. By June/July 2012 the National Health Laboratory
Service Laboratory (NHLS) had performed 54,232 Xpert MTB/RIF tests in Gauteng Province
[12]. Of these MTB was detected in 12.6% (n = 6,857) and 6.67% of these were resistant to
rifampicin (n = 457). Based on the NHLS data the City of Johannesburg, which has an esti-
mated overall HIV prevalence of 11.1%, reported 42,924 Xpert MTB/RIF tests between July
2011 and June 2012 [13].
As illustrated in Fig 1, symptomatic patients presenting at one of the city’s primary health-
care clinics provide 1–2 sputum samples, which are sent to the NHLS for the diagnosis of TB
and rifampicin resistance or multi-drug resistance (rifampicin and isoniazid resistance). The
NHLS sends all RR-TB results back to the diagnosing clinic and to the COJ TB coordinator,
where the results are recorded and a DR-TB case registration number is assigned. The COJ
assigns each patient to a district TB coordinator who contacts and refers the patient to appro-
priate care and reports the outcome of the tracing to the COJ within 3–5 days. At the diagnos-
ing clinic, a nurse records the results in the TB suspect register and refers the patient to an
appropriate DR-TB treatment center. Once the patient arrives at the DR-TB treatment center,
the patient is initiated onto DR-TB treatment and the DR-TB treatment center records the
patient information and DR-TB case registration number (obtained from COJ). Alternatively,
the DR-TB treatment center may decide to transfer the patient to a more appropriate facility
(e.g. if the first DR-TB treatment center is an outpatient clinic and the patient should be admit-
ted as an inpatient). The COJ maintains an electronic register of diagnosed patients and also
has paper records of tracing activities.
During the study period, DR-TB patients within COJ could be referred to one inpatient
treatment center or one of three outpatient treatment centers. Sizwe Tropical Disease Hospital
(STDH), the inpatient treatment center, serves as a referral center for all DR-TB in Gauteng
Province, where Johannesburg is located [14]. Prior to decentralization in 2011, all MDR-TB
and XDR-TB patients in the province were treated at STDH; currently all XDR-TB patients
are still treated there. Between January 2007 and December 2010 a total of 2005 MDR-TB pa-
tients were admitted to STDH [14]. Records for patients initiated onto treatment for MDR-TB
and XDR-TB at STDH are entered directly into the national electronic DR-TB register, which
is called EDRweb.
In 2011, three outpatient clinics, at Charlotte Maxeke Johannesburg Academic Hospital
(CMJAH), Helen Joseph Hospital (HJH), and South Rand Hospital (SRH), were authorized
to initiate and treat DR-TB on an outpatient basis. Eligibility criteria for outpatient initiation
of DR-TB treatment were established by the National Department of Health and take into
account transmission risk (smear negative or extra-pulmonary TB), clinical condition (e.g.
body mass index>18.5 kg/m2), social support, and stable accommodation [10]. Patients are
also treated at the outpatient facility if there are no beds available at STDH or if the patient
refuses to be admitted for inpatient care. All three facilities maintain on-site electronic clinical
patient DR-TB registers.
We enrolled in the study all adults (18 years and older) who had a diagnosis of laboratory-
confirmed RR-TB reported to the COJ between July 2011 and June 2012. We excluded patients
who enrolled in care at one of the four DR-TB treatment sites after transfer from another dis-
trict, province, or country.
Drug resistant tuberculosis in South Africa—Linkage to care
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Fig 1. Schematic of the procedures and structures established within district health system for the
follow-up of all patients diagnosed with RR-TB.
https://doi.org/10.1371/journal.pone.0181238.g001
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Diagnostic algorithms
Xpert MTB/RIF was implemented as the first-line diagnostic test for tuberculosis in South
Africa during the study period. Prior to 2011, the TB diagnostic algorithm relied on smear mi-
croscopy for cases of suspected tuberculosis. Line probe assay (LPA; GenoType MTBDRplus
Hain-Life-Science) with culture and phenotypic DST were only done in cases of suspected
drug-resistance such as contact of person with known DR-TB; relapse and treatment failure
[15]. With implementation of Xpert MTB/RIF universal DST for rifampicin became the stan-
dard of care. Xpert MTB/RIF roll-out by the National Health Laboratory Services (NHLS) in
the City of Johannesburg began in August 2011 with full utilization by January 2012 [12]. Cer-
tain sites had earlier access to Xpert MTB/RIF prior to implementation by the NHLS through
validation research studies.
Outcomes, data, and data analysis
The primary outcome of the study was the proportion of patients who initiated DR-TB treat-
ment at one of the city’s four treatment sites within six months of sputum collection. To de-
termine who initiated DR-TB treatment we matched eligible patients in the COJ register to
electronic registers at the sites. Study staff worked with facilities and the COJ to verify and cor-
rect patient information (e.g. to correctly record DR-TB registration numbers in facility regis-
ters and query specific cases where diagnosis date or treatment initiation date preceded the
sputum collection date). For patients in the COJ register who could not be matched to the elec-
tronic registers by DR-TB case registration number or where the registration number was
missing, probabilistic matching using first name, surname, date of birth, and sex was used to
match individuals. For patients who still could not be matched, we then matched on (i) first
three initials of name and surname, date of birth and sex, (ii) first three initials of name and
surname, year of birth and sex, and (iii) a four-character code created using a phonetic algo-
rithm (Soundex) to account for minor differences in spelling (e.g. ‘Ngcobo’ vs ‘Ngobo’).
Matched pairs were manually checked and verified by two independent evaluators. DR-TB
treatment initiation date was obtained from the electronic registers at the sites for patients
who could be matched.
The outcomes of COJ tracing for all patients diagnosed with RR-TB were obtained from the
COJ register and were defined as died, moved or transferred out of the city, lost (untraceable),
or successfully traced and referred.
Variables including first name, surname, date of birth, sex, tracing outcome, treatment ini-
tiation date, and address were obtained from the COJ electronic register. In addition, variables
collected for each patient such as disease classification, diagnosis method and diagnosis date
(obtained from NHLS), smear microscopy result, and site of disease were also obtained from
the registers. We further classified RR-TB with unknown or pending sensitivities to other
drugs according to the diagnosis method used: Xpert MTB/RIF, LPA or phenotypic DST. In
addition, we used the address the patient recorded in the COJ electronic register to calculate
the distance from the diagnosing/referring clinic to the patient’s residence and, for those initi-
ating treatment, from the patient’s residence to the DR-TB treatment center using Google
Maps and SAS version 9.3. We further divided distance from the patient’s residence to diag-
nosing/referring clinic into quintiles. The first and second quintile were groups and labeled
“near” (<11.2 km), the third labelled intermediate (11.2–54.3 km) and the third to fifth quin-
tile were grouped and labelled far ( 54.3 km) [16–18].
In the analysis, demographic and clinical characteristics are presented using proportions
for categorical variables and medians with corresponding interquartile ranges (IQR) for con-
tinuous variables. We first estimated the proportion of the population who experienced the
Drug resistant tuberculosis in South Africa—Linkage to care
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primary outcome. We used competing risk regression method from Fine and Gray to fit a
proportional subdistribution hazard model [19,20]. Death was considered a competing risk,
which arises when the event of interest (initiation of DR-TB treatment) can be impeded by a
prior event of a different type (e.g. death). Patient time accrued from the date of diagnosis
until the earliest of DR-TB treatment initiation, death, lost/transferred out of the city/moved,
or 6 months’ follow-up after diagnosis. In instances where the transfer out date was missing,
the date of last contact with the patient, as recorded by the TB district coordinator, was used as
the outcome date. Subdistribution hazard ratios (sHR) with 95% confidence intervals (CI) are
presented. Categorized age, sex, disease classification and diagnosis method were included in
the adjusted model along with other a priori identified characteristics.
To identify predictors of all-cause mortality, we used Cox proportional hazard regression to
estimate a hazard ratio (HR) and corresponding 95% confidence interval (CI). Patient time
accrued from the date of diagnosis until the earliest of all-cause mortality, lost (untraceable),
transferred out of the city/moved, or 6 months’ follow-up after diagnosis. Crude and adjusted
hazard ratios (HR) with 95% confidence intervals (CI) are presented.
We also compared median time from sputum collection to treatment initiation by disease
classification, site of treatment initiation (decentralized-outpatient vs centralized-inpatient)
and diagnosis method using the student t test for parametric or Kruskal-Wallis for non-
parametric data. We also tested the association between treatment site and initiating treatment
within five days of diagnosis using log-binomial regression with crude risk ratios and 95% con-
fidence intervals. All analyses were carried out using SAS version 9.3 (SAS Institute, Cary,
North Carolina, USA).
This study was approved by the Human Research Ethics Committee (Medical) of the Uni-
versity of the Witwatersrand (Wits HREC M130601). Participants did not provide written or
verbal consent to participate in the study as all data analyzed were collected as part of routine
diagnosis and treatment.
Results
We enrolled 594 patients in the study. As described in Table 1, they had a median (IQR) age of
34 (29–42) years, and 48.3% were female. Most were diagnosed by LPA (281, 47.3%) or Xpert
MTB/RIF (258, 43.4%), with a few by phenotypic DST (30, 5.1%) or by unknown (missing)
diagnostic method (25, 4.2%). 320 patients (53.8%) had MDR-TB, 158 (26.6%) had rifampicin
resistant TB by Xpert MTB/RIF with no additional drug susceptibility results available, 102
(17.2%) had rifampicin mono-resistance, and 14 (2.4%) had XDR TB.
Only 43% (256/594) of the patients diagnosed with DR-TB in COJ initiated treatment at
one of the four treatment sites within six months of diagnosis. Of the 594 laboratory confirmed
cases reported to the COJ, 60.9% (362/594) were successfully traced and referred for treatment;
the 256 who actually started treatment represent 70.7% of these (Fig 2). Among the 338
patients (57.0%) who did not initiate treatment, 104 died before treatment was started, 24
transferred out or moved out of the province and 104 could not be traced (lost). Of the 362
patients who were successfully traced and referred, 106 failed to link to care after referral.
According to the COJ tracing outcome, median time from sputum collection to death was 19
days (IQR 10–30) and from sputum collection to other reported outcome (lost/untraceable or
transferred out of the city/moved) was 14 days (IQR 8–34).
Among those who did start treatment, 34.4% (88/256) initiated treatment at the central-
ized-inpatient DR-TB treatment center, and 65.6% (168/256) initiated at one of the three
decentralized-outpatient sites. Demographic and clinical characteristics of those who initiated
treatment are presented in Table 2.
Drug resistant tuberculosis in South Africa—Linkage to care
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For the sample as a whole, the median time from sputum collection to diagnosis was 26
days (IQR 7–36) and from sputum collection to treatment initiation 33 days (IQR 12–52;
n = 256). Time from sputum collection to treatment initiation varied by type of treatment
center: 42 days (IQR 29–55) and 22 days (9–50) for inpatient (n = 88) and outpatient sites
(n = 168), respectively (p = 0.03). This interval also varied by diagnostic method for diagnosis
of rifampicin resistance (e.g. Xpert MTB/RIF vs LPA and phenotypic DST): 17 days (9–47), 38
days (23–54), and 81 days (49–115) for Xpert MTB/RIF (n = 107), LPA (n = 129), and pheno-
typic DST (n = 8), respectively (p = 0.002). Table 3 summarizes median time from sputum col-
lection to treatment initiation, by treatment site and diagnostic method.
Only ten percent (25/256) of patients diagnosed with RR-TB initiated treatment within five
days, which is the national target [21]. Those starting treatment at the inpatient facility were
more likely to initiate after five days (RR 1.15 95% CI 1.08–1.23). More patients at the outpa-
tient facilities started treatment within five days than at the inpatient facility (1% [1/88] vs 14%
[24/168]), though the proportion achieving this target, 14%, was very low even at the decen-
tralized facilities.
Table 1. Demographic and clinical characteristics of patients who had a diagnosis of laboratory-confirmed RR-TB reported to the COJ for tracing
between July 2011 and June 2012 (n = 594).
Characteristic Description N = 594
Gender Male n,% 307 (51.7%)
Female 287 (48.3%)
Age, years Median, IQR 34 (29–42)
< 30 n, % 162 (27.3%)
30–45 308 (51.9%)
45–60 105 (17.7%)
 60 19 (3.2%)
Disease classification RR-TB by Xpert^ n, % 158 (26.6%)
RR-TB (mono and poly)^^ 102 (17.2%)
MDR-TB 320 (53.8%)
XDR TB 14 (2.4%)
Diagnosis method Xpert MTB/RIF n, % 258 (43.4%)
GenoType MTBDRplus line probe assay 281 (47.3%)
Phenotypic drug susceptibility testing 30 (5.1%)
Unknown 25 (4.2%)
AFB smear microscopy status Positive n, % 144 (24.2%)
Negative 78 (13.1%)
Unknown 372 (62.7%)
Site of disease Pulmonary n, % 581 (97.8%)
Extra-pulmonary 13 (2.2%)
Treatment site Helen Joseph Hospital (outpatient) n, % 70/256 (27.3%)
Charlotte Maxeke Hospital (outpatient) 61/256 (23.8%)
South Rand Hospital (outpatient) 37/256 (14.5%)
Sizwe Tropical Disease Hospital (inpatient) 88/256 (34.4%)
Location of residence Distance from diagnosing/referral facility to residence, km (n = 402; 67.7%) Median, IQR 13 (11.2–54.3)
Distance from DR-TB treatment facility to residence, km (n = 249; 97.3%) Median, IQR 11.2 (7.7–23.0)
RR-TB rifampicin resistant tuberculosis; MDR-TB multi-drug resistant TB; XDR TB extensively drug resistant TB; km kilometer; AFB acid fast bacilli; IQR
inter-quartile range
^RR-TB diagnosed by Xpert with unknown or pending sensitivities to other drugs
^^mono- or poly-resistant is resistance to rifampicin alone or rifampicin plus another first-line drug (other than isoniazid), confirmed by LPA or DST.
https://doi.org/10.1371/journal.pone.0181238.t001
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Fig 2. Schematic showing the proportion of those diagnosed with RR-TB in the COJ who were
successfully traced and referred and who initiated treatment along with other tracing outcomes
including death, moved or transferred out of the city and untraceable.
https://doi.org/10.1371/journal.pone.0181238.g002
Drug resistant tuberculosis in South Africa—Linkage to care
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Factors predicting treatment initiation and mortality
We demonstrate that compared to those diagnosed by Xpert MTB/RIF, patients diagnosed by
phenotypic DST were less likely to initiate treatment (sHR 0.39 95% CI 0.20–0.75). Patients
diagnosed with XDR-TB were also less likely to link to care (sHR 0.38 95% CI 0.15–0.98). Dis-
tance from residence to referring facility was a significant predictor of treatment initiation
(Table 4).
Time to treatment initiation varied by diagnostic method, and this then may explain some
of the differences observed in mortality before treatment initiation. Those diagnosed by LPA
(HR 2.57 95% CI 1.31–5.03) and phenotypic DST (HR 3.98 95% CI 1.58–9.99) were more
likely to die before treatment initiation, compared to those diagnosed by Xpert MTB/RIF.
Patients classified as having XDR TB (HR 3.35 95% CI 1.33–8.42) were more likely to die
before treatment initiation compared to those with MDR-TB. Conversely, those classified as
Table 2. Comparison of case characteristics between those initiated treatment at outpatient and inpatient sites (n = 256).
Characteristic Description Outpatient sites
(n = 168)
Inpatient site
(n = 88)
P value
Sex Female n,% 89 (53.0%) 41 (46.6%) 0.332
Age, years Median,
IQR
34 (29–42) 35 (29–44) 0.773
< 30 n, % 49 (29.2%) 24 (27.3%)
30–45 83 (49.4%) 42 (47.7%)
45–60 30 (17.8%) 20 (22.7%)
 60 6 (3.6%) 2 (2.3%)
Classification RR-TB by Xpert n, % 56 (33.3%) 1 (1.1%) <0.005
RR-TB 49 (29.2%) -
MDR-TB 63 (37.5%) 84 (95.5%)
XDR TB - 3 (3.4%)
Diagnosis Xpert MTB/RIF n, % 81 (48.2%) 26 (29.6%) 0.022
MTBDRplus LPA 75 (44.6%) 54 (61.4%)
DST 6 (3.6%) 2 (2.3%)
Unknown 6 (3.6%) 6 (6.8%)
AFB smear microscopy
status
Negative n, % 24 (14.3%) 8 (9.1%) 0.155
Positive 40 (23.8%) 30 (34.1%)
Unknown 104 (61.9%) 50 (56.8%)
Site of disease Pulmonary n, % 165 (98.2%) 83 (94.3%) 0.089
Extra-pulmonary 3 (1.8%) 5 (5.7%)
Diagnosed at Clinic/CHC n,% 113 (67.3%) 38 (43.2%) 0.099
Hospital 55 (32.7%) 50 (56.8%)
HIV status Positive n,% 149 (88.7%) Not available Not
Negative/Unknown 19 (11.3%) applicable
Location of residence Distance from diagnosing/referral facility to
residence, km
Median,
IQR
12.0 (11.2–54.5)
(n = 161)
54.2 (11.3–69.5)
(n = 88)
0.726
Distance from DR-TB treatment facility to
residence, km
Median,
IQR
13.0 (7.8–29.0)
(n = 162)
11.1 (7.6–12.0)
(n = 87)
0.091
Diagnosis site Proportion diagnosed and treated at the same
site
n, % 43 (25.6%) 0 (0%) Not
applicable
RR-TB rifampicin resistant tuberculosis; MDR-TB multi-drug resistant TB; XDR TB extensively drug resistant TB; AFB acid fast bacilli; LPA line probe
assay; phenotypic DST drug susceptibility testing; HIV human immunodeficiency virus; km kilometer; CHC community health centers IQR inter-quartile
range
https://doi.org/10.1371/journal.pone.0181238.t002
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having rifampicin mono-resistance were less likely to die before treatment initiation (HR 0.51
95% CI 0.26–1.00). Interestingly, patients who lived near to (sHR 1.64 95% CI 1.17–2.30) and
those who lived far (sHR 3.39 95% CI 2.54–4.52) from the diagnosing/referring facility were
more likely to initiate treatment. Those who lived greater distances from the diagnosing/refer-
ring facility were also less likely to die before treatment initiation (far vs intermediate HR 0.09
95% CI 0.02–0.36) (Table 5).
Discussion
In this study, fewer than half (43.0%) the patients diagnosed with DR-TB in the City of Johan-
nesburg in 2011–2012 initiated appropriate treatment within six months of diagnosis despite
the quadrupling of facilities offering DR-TB treatment under the new decentralization frame-
work–from one inpatient facility to one inpatient plus three outpatient facilities. The propor-
tion of patients who initiated treatment within six months (43.0%) is similar to national
estimates reported for South Africa in the 2013 WHO Global TB report (6 494 cases started on
MDR-TB treatment/15 419 cases of laboratory confirmed MDR-TB for 2012; 42%) [22]. Pre-
treatment loss to follow-up among drug sensitive patients in Africa ranges from 6 to 38%, and
is similar among patients with drug resistant TB [23–26]. We showed high pre-treatment loss
of 17.8% and many patients (17.5%) died before DR-TB treatment could be initiated. Only 3
out of 5 patients diagnosed with DR-TB (60.9%) could be traced and referred for treatment.
Although decentralization and the implementation of Xpert MTB/RIF for the diagnosis of TB
and rifampicin resistance has resulted in a significant reduction in time to treatment initiation
as reported in previous studies [26], these programmatic changes did not solve the problem of
loss of patients between diagnosis and treatment initiation seen in our cohort. This initial loss
from care has contributed to lack of improvement in treatment outcomes [27]. This is an area
where additional health system strengthening is required.
For the study period, we report a median time to treatment initiation of 33 days, which is
consistent with what has been reported elsewhere in the country following implementation of
decentralized treatment. Results from Khayelitsha, Cape Town report that the introduction of
Table 3. Median time from sputum collection to treatment initiation, by treatment site and diagnostic method and proportion initiating treatment
by treatment site (n = 256).
All Xpert MTB/RIF GenoType MTBDRplus line probe
assay
Phenotypic drug susceptibility
testing
P value
Median time from sputum collection to treatment initiation
DR-TB treatment site
All (n = 256) 17 (9–47) 38 (23–54) 81 (49–115) 0.002
Outpatient (n = 168) 13 (9–28) 41 (6–62) 75 (28–133) 0.01
Inpatient (n = 88) 49 (33–64) 37 (29–46) 89 (81–97) 0.04
AFB smear microscopy status
Positive (n = 70) 15 (1–42) 32 (7–42) 81 (75–107) 0.003
Negative (n = 32) 54 (45–62) 97 (28–133) 0.316
Proportion initiating DR-TB treatment by DR-TB treatment site
Outpatient N = 107 N = 129 N = 8
Helen Joseph Hospital (outpatient) 18 (16.8%) 46 (35.7%) 4 (50.0%)
Charlotte Maxeke Hospital
(outpatient)
35 (32.7%) 21 (16.3%) 1 (12.5%)
South Rand Hospital (outpatient) 28 (26.2%) 8 (6.2%) 1 (12.5%)
Inpatient
Sizwe Tropical Disease Hospital 26 (24.3%) 54 (41.9%) 2 (25.0%)
https://doi.org/10.1371/journal.pone.0181238.t003
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LPA during 2007–2008 was associated with a decrease in time to treatment initiation from 76 to
50 days. Decentralization during 2008–2011 saw a further reduction to 28 days (IQR 16–40) [26].
Our results show that time to treatment initiation varied by diagnostic method and whether the
patient was smear positive or negative, and the reason for the test. Time from sputum collection
to diagnosis differed by diagnostic method, which in turn delayed reporting, referral, and treat-
ment initiation. Xpert MTB/RIF was implemented as the first-line diagnostic test for tuberculosis
in South Africa during the study period, as such some patients some patients in the early study
period would have been diagnosed under the culture and LPA diagnostic algorithm. Time to
treatment initiation has improved significantly following implementation of Xpert MTB/RIF in
South Africa, from a median delay of 28–62 days [26,28] with the use of Genotype MTBDRplus
line probe assay, to 8–10 days since implementation of Xpert MTB/RIF [26,29].
Negative sputum smears are also correlated with delays for TB treatment in those diagnosed
by LPA [30,31] because LPAs are generally performed on culture, rather than directly on speci-
men, in smear negative cases, resulting in significant delays in therapy (24 days vs 62 days)
[32]. In addition to the diagnostic method used, the burden of TB in the setting may also con-
tribute to delays in initiation. High numbers of RR-TB positive cases may result in delays in
home visits or reporting of laboratory results, which can result in delayed or inappropriate
Table 4. Subdistribution hazard regression to identify predictors treatment initiating among patients diagnosed with RR-TB in the COJ between
July 2011 and June 2012.
Proportion initiating TB treatment (n = 256)
Characteristic Treatment initiation/N (%) Crude sHR^ (95% CI) Adjusted sHR^ (95% CI)
Gender Female 130/287 (45.3%) 1.0 1.0
Male 126/307 (41.0%) 0.87 (0.68–1.12) 0.88 (0.68–1.14)
Age, years < 30 73/162 (45.1%) 1.0 1.0
30–45 125/308 (40.6%) 0.92 (0.69–1.24) 0.99 (0.73–1.33)
45–60 50/105 (47.6%) 1.13 (0.79–1.63) 1.23 (0.84–1.79)
 60 8/19 (42.1%) 1.09 (0.49–2.43) 1.20 (0.50–2.88)
Classification RR-TB by Xpert 147/320 (45.9%) 0.91 (0.65–1.26) 0.82 (0.54–1.24)
RR-TB 57/158 (36.1%) 1.04 (0.76–1.41) 1.10 (0.79–1.53)
MDR-TB 49/102 (48.0%) 1.0 1.0
XDR TB 3/14 (21.4%) 0.39 (0.13–1.19) 0.38 (0.15–0.98)
Diagnosis Xpert MTB/RIF 107/258 (41.5%) 1.0 1.0
LPA 129/281 (45.9%) 0.97 (0.74–1.27) 0.79 (0.55–1.16)
DST 8/30 (26.7%) 0.43 (0.22–0.87) 0.39 (0.20–0.75)
Unknown 12/25 (48.0%) 1.08 (0.59–1.96) 0.85 (0.44–1.65)
AFB smear microscopy status Positive 70/144 (48.6%) 1.35 (0.89–2.04)
Negative 32/78 (41.0%) 1.0
Unknown 154/372 (41.4%) 1.21 (0.84–1.74)
Site of disease EPTB 8/13 (61.5%) 1.0 1.0
Pulmonary 248/581 (42.7%) 0.70 (0.38–1.26) 0.82 (0.40–1.67)
Distance from residence to referring facility Near 57/119 (47.9%) 1.60 (1.15–2.24) 1.64 (1.17–2.30)
Intermediate 118/191 (61.8%) 1.0 1.0
Far 74/92 (80.4%) 3.47 (2.63–4.56) 3.39 (2.54–4.52)
sHR subdistribution hazard ratio
^sHR from competing risk regression accounting for death. CI confidence interval; EPTB extra-pulmonary TB; AFB acid fast bacilli; RR-TB rifampicin
resistant TB; MDR-TB multi-drug resistant TB; XDR extensively drug resistant TB; LPA line probe assay; phenotypic DST drug susceptibility testing;
Reference = HR 1.00
https://doi.org/10.1371/journal.pone.0181238.t004
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treatment and missed opportunities to prevent transmission. In our setting, Xpert MTB/RIF
has been used as the initial diagnostic test since late 2011 for TB. Smear and culture are or-
dered if Xpert MTB/RIF negative and the patient is still symptomatic for TB. LPA is done on
smear positive sputa or on MTB+ culture isolates whereas if smear negative, a culture is grown
and then LPA is done on the culture, which in turn delays reporting, referral, and treatment
initiation. Our study coincides with the rollout of Xpert MTB/RIF with laboratories in high
burden sub-districts receiving Xpert MTB/RIF machines first. Xpert MTB/RIF implementa-
tion was accompanied by considerable operational and logistical challenges [9], and as a result
not all sites had access to Xpert MTB/RIF during the early part of the study. Full, nation-wide,
capacitation was reached in September 2013, however in the City of Johannesburg full capacity
was reached in early 2012 [15].
In our study, patients diagnosed by LPA and phenotypic DST were more likely to die before
treatment initiation. The median time from sputum collection to treatment initiation for
patients diagnosed by these methods—38 days and 81 days for LPA and phenotypic DST,
respectively, compared to just 17 days for diagnosis by Xpert—may in itself place patients at
risk: in a 2010 study from KwaZulu Natal, South Africa, 40% of MDR-TB and 51% of XDR TB
patients died within 30 days of sputum collection [7]. A recent study demonstrated the impact
of reducing time to MDR-TB treatment initiation on treatment outcomes. The study showed
that time to MDR-TB treatment initiation was lower in the group diagnosed using the LPA-
based algorithm compared to those diagnosed with the culture-based algorithm (50 and 66
Table 5. Unadjusted and adjusted predictors of mortality among patients diagnosed with RR-TB in the COJ between July 2011 and June 2012.
Mortality (n = 104)
Characteristic Mortality/N (%) Crude Hazard Ratio (95% CI) Adjusted Hazard Ratio (95% CI)
Gender Female 46/287 (16.0%) 1.0 1.0
Male 58/307 (18.9%) 1.14 (0.77–1.69) 0.98 (0.65–1.48)
Age, years < 30 20/162 (12.4%) 1.0 1.0
30–45 63/308 (20.5%) 1.85 (1.09–3.13) 1.94 (1.13–3.33)
45–60 18/105 (17.1%) 1.55 (0.81–2.98) 1.52 (0.77–3.01)
 60 3/19 (15.8%) 1.40 (0.41–4.75) 1.26 (0.37–4.35)
Classification RR-TB by Xpert 23/158 (14.6%) 0.93 (0.57–1.51) 1.80 (0.87–3.76)
RR-TB 13/102 (12.8%) 0.61 (0.32–1.16) 0.51 (0.26–1.00)
MDR-TB 61/320 (19.1%) 1.0 1.0
XDR TB 7/14 (50.0%) 2.86 (1.23–6.62) 3.35 (1.33–8.42)
Diagnosis Xpert MTB/RIF 34/258 (13.2%) 1.0 1.0
LPA 56/281 (19.3%) 1.41 (0.92–2.17) 2.57 (1.31–5.03)
DST 11/30 (36.7%) 2.75 (1.32–5.73) 3.98 (1.58–9.99)
Unknown 3/25 (12.0%) 0.85 (0.26–2.76) 1.43 (0.39–5.16)
AFB smear microscopy status Positive 26/144 (18.1%) 0.78 (0.43–1.43)
Negative 19/78 (24.4%) 1.0
Unknown 59/372 (15.9%) 0.65 (0.38–1.11)
Site of disease EPTB 1/13 (7.7%) 1.0 1.0
Pulmonary 103/581 (17.7%) 2.55 (0.36–18.30) 3.11 (0.43–22.61)
Distance from residence to referring facility Near 25/119 (21.0%) 0.98 (0.62–1.57) 0.99 (0.62–1.62)
Intermediate 21/191 (11.0%) 1.0 1.0
Far 2/92 (2.2%) 0.09 (0.02–0.36) 0.09 (0.02–0.36)
CI confidence interval; EPTB extra-pulmonary TB; AFB acid fast bacilli; RR-TB rifampicin resistant TB; MDR-TB multi-drug resistant TB; XDR extensively
drug resistant TB; LPA line probe assay; phenotypic DST drug susceptibility testing; Reference = HR 1.00
https://doi.org/10.1371/journal.pone.0181238.t005
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days) which resulted in better treatment outcomes, both in terms of treatment success (65.2%
vs 44.8%) and mortality (7.6% vs 15.9%) [32]. Prior to implementation of Xpert MTB/RIF as
the first line diagnostic test, phenotypic DST and LPA were done on patients suspected of
having DR-TB due to prior treatment failure, default, or contact with a person with known
DR-TB [14]. As a result the groups of patients diagnosed in the previous algorithm may reflect
a sicker population of patients with longer standing undiagnosed/untreated tuberculosis at
higher risk of early mortality. As a result the group diagnosed by Xpert MTB/RIF may not be
equivalent than those diagnosed by LPA.
We found that patients who lived near (<11.2 km) to the diagnosing/referring facility were
more likely to initiate treatment compared to those at a middle or intermediate distance. This
was supported by the finding that patients who lived in the same COJ region as the diagnos-
ing/referring facility (RR 1.24 95% CI 0.92–1.67) or the same region as one of the treatment
facilities (RR 1.47 95% CI 1.14–1.90) were more likely to initiate treatment. Contradictory to
other reports, we also found that patients who lived far (54.3 km) from the diagnosing/refer-
ring facility were more likely to initiate treatment. Therefore, according to distance from diag-
nosing/referring facility, we found the highest rates of initiation among two groups, those who
live very close and those who live very far, with less initiation for those at a middle distance
from the diagnosing/referring facility (e.g. not close to work or home). There are a number of
possible factors that may help explain why patients who live very far from the diagnosing/
referring facility are more likely to initiate treatment. There could be a component of selection
bias as those patients located far from the urban center who manage to seek out care and get
diagnosed with DR-TB may reflect a sub-set of patients more likely to engage in care. Also,
patients who are still well enough to work may be using the facility closest to their employ-
ment, as facilities are only open during working hours, rather than near their residential
address (which is typically located outside of the cities and places of work). Another contribut-
ing factor may be the use of public transportation (e.g. patients may choose to travel to a more
distant clinic as it requires less taxi switches, cost and time). Some other patient related factors
that may contribute to delaying treatment include first consulting with a traditional healer,
financial constraints, stigmatization and misperceptions about TB causes and symptoms [30,
33–36]. Type of health care provider (e.g. initial visit to a specialized TB facility) may be an
important factor for patients seeking care [37,38]. Provider factors such as infrastructure of
health services, diagnostic facilities, availability of trained staff, quality of services and effective
supervision may persuade patients to travel long distances to access and utilize healthcare ser-
vices [39] Further exploration of this unexpected finding is required. The current study was
retrospective and was not designed to explore the patients’ health seeking behaviour.
COJ tracing successfully referred 60.9% and traced an additional 21.5% (n = 128; deaths
and transfer out) of patients diagnosed with DR-TB. Consistent with other reports from this
region, 79% of those referred initiated treatment [40]. Guidelines recommend that tracing
should be completed in 3–5 days; we observed a median of 14 days. Reducing this delay, by
investing more in the efforts of TB district coordinators, may increase the proportion of
patients referred and reduce pre-treatment mortality. It is also important to understand why
close to a fifth (17.8%) of patients who were referred did not initiate treatment within COJ in
the six-month follow up interval of study observation. Some may have started treatment at
another facility outside of COJ or after six months, but existing tracking systems do not allow
this to be determined. An additional 7% (n = 29; 8 diagnosed by Xpert MTB/RIF and 21 by
LPA) of patients who were referred had a treatment initiation date prior to the diagnosis date.
Since these are likely to represent a previous episode (i.e. initiation date median 3.2 months
IQR 1.3–6.8 before the diagnosis date), they were assumed not to have initiated treatment for
this RR-TB episode.
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Results should be considered in light of the study limitations. First, as this was a retrospec-
tive medical register review there were some variables, such as HIV status, travel time or travel
cost and previous history of TB, which could not be included in the analysis. Moreover, al-
though death dates were available for most of those who died (93%), dates of other outcomes
(e.g. moved or transferred) were reported for only a third of those concerned (34%), requiring
us to use the date of last contact with patient as recorded by the district coordinator as a proxy
date. Since death is ascertained from family reports and passive tracing by the district TB coor-
dinator, it is possible that some of those lost (n = 104) may have died, resulting in an underesti-
mation of mortality prior to treatment initiation. Although disease classification was recorded
from the COJ register, there may have been some misclassification due to inadequate second-
line resistance testing, and as such, several people classified as RR-TB may be MDR-TB or
(pre) XDR TB. Though we attempted to verify the diagnostic test and data, using the COJ reg-
ister and NHLS laboratory reports, diagnosis method and the date of diagnosis may have been
incorrect in some instances. For example, if the initial diagnostic test (e.g. Xpert MTB/RIF)
was missing we used LPA and the date of the LPA as the diagnostic test.
Second, since the starting point of the study was the COJ register (NHLS sends all RR-TB
results back to the diagnosing clinic and to the COJ TB coordinator who records the result and
assigns a TB case registration number) we could not ascertain if all laboratory diagnosed
RR-TB cases were registered in the COJ register and therefore included in the study. Albeit
minimal, this may have led to an underestimation of the number of cases of laboratory con-
firmed RR-TB, in the COJ, for the study period. In addition, we relied on the COJ register for
linkage outcomes and dates of linkage outcomes for SDTH patients in the cohort and did not
access the DR-TB register or EDRweb for this treatment site. Finally, although we attempted
to match eligible patients using the DR-TB case registration number, in some cases this was
missing in the electronic registers at the site, leading us to underestimate the proportion of
patients who initiated treatment. Although we used various combinations of patient first
name, surname, date of birth and gender to match patients in the COJ register to electronic
registers at the sites, we cannot be certain that no patients were missed.
Conclusion
Despite these limitations, our data indicate very high rates of failure to initiate appropriate
RR-TB treatment for patients diagnosed with drug-resistant TB in the City of Johannesburg.
Though it is surely a step in the right direction, offering treatment at decentralized sites alone
is not sufficient; improvements in linking patients diagnosed with RR-TB to effective treat-
ment remains a high priority.
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